This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956146.

Andreas Lehmann

Biopharmaceutical Scientist, Merck Healthcare KGaA

(Co-)supervisor of ESRs 8 and 10.

Dr. Andreas Lehmann studied pharmacy at the Goethe University in Frankfurt (Germany) from 2009 to 2014. During his doctoral thesis (2014-2018 in the group of Jennifer Dressman) he focused on the dangers, the spread and the possibilities of combating counterfeit medicines in Africa. Before Andreas Lehmann started as a biopharmaceutical scientist at Merck Healthcare (Center of Excellence for Biopharmaceutics) in 2020, he worked at Merz and Galenicon GmbH. In addition to his work at Merck, he gives lectures on statistics and pulmonary biopharmacy at Goethe University. He has supervised pharmaceutical interns, bachelor students and doctoral candidates. In addition, Andreas is chairman of “Hilfe für Akwa e.V.”, an association that improves the medical infrastructure in Nigeria.


  • Lehmann, A., Hofsäss, M. and Dressman, J. (2018) Differences in drug quality between South Africa and Germany. Journal of Pharmacy and Pharmacology, 70(10), pp. 1301-1314. DOI: 10.1111/jphp.12985
  • Lehmann, A., Katerere, D.R. and Dressman, J. (2018) Drug quality in South Africa: a field test. Journal of Pharmaceutical Sciences, 107(10), pp. 2720-2730. DOI: 10.1016/j.xphs.2018.06.012
  • Koczwara, A. and Dressman, J. (2017) Poor-quality and counterfeit drugs: a systematic assessment of prevalence and risks based on data published from 2007 to 2016. Journal of Pharmaceutical Sciences, 106(10), pp. 2921-2929. DOI: 10.1016/j.xphs.2017.05.018
  • Ude, M., Koczwara, A. and Ude, C. (2014) Drug-related problems in placing and blister-packaging: Correct handling in practice. PZ PRISMA, 21(1), pp. 40-44.